Use of allopurinol in children with acute lymphoblastic leukemia to reduce skewed thiopurine metabolism.
Pediatr Blood Cancer
; 61(6): 1114-7, 2014 Jun.
Article
em En
| MEDLINE
| ID: mdl-24376133
ABSTRACT
Mercaptopurine (6-MP), a critical component of acute lymphoblastic leukemia (ALL) therapy, is metabolized to 6-thioguanine (6-TGN) which is responsible for its anti-leukemic effect, and to 6-methylmercaptopurine nucleotides (6-MMPN/6-MMP) which can be hepatotoxic. Some patients preferentially metabolize 6-MP to 6-MMPN which may increase the risk of liver injury, reduce serum levels of 6-TGN and potentially increase the risk of relapse. The addition of allopurinol to oral 6-MP has been shown to optimize metabolism towards 6-TGN in patients with inflammatory bowel disease (IBD); however, this use has not been reported in patients undergoing treatment for ALL.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Alopurinol
/
Leucemia-Linfoma Linfoblástico de Células Precursoras
/
Mercaptopurina
/
Antimetabólitos Antineoplásicos
Tipo de estudo:
Etiology_studies
Limite:
Adolescent
/
Child, preschool
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Pediatr Blood Cancer
Assunto da revista:
HEMATOLOGIA
/
NEOPLASIAS
/
PEDIATRIA
Ano de publicação:
2014
Tipo de documento:
Article